Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125515 · ClinicalTrials.gov registry record · Phase 2
Memantine and Naltrexone Treatment for Opioid Dependence
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT00125515 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 81 participants.
The verdict
NCT00125515, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The goal of this study is to test the efficacy of memantine (a noncompetitive NMDA receptor antagonist) as an adjunct to the maintenance treatment with naltrexone in detoxified heroin-dependent individuals.
Interventions
- DRUG Memantine
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00125515
The ClinicalTrials.gov registry entry for NCT00125515 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Memantine is the first listed.
NCT00125515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00125515 about?
NCT00125515 is a clinical study titled "Memantine and Naltrexone Treatment for Opioid Dependence". The goal of this study is to test the efficacy of memantine (a noncompetitive NMDA receptor antagonist) as an adjunct to the maintenance treatment with naltrexone in detoxified heroin-dependent individuals.
What is the current status of trial NCT00125515?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2005-06. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00125515?
The interventions under investigation include: Memantine (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT00125515?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.